SAN

82.08

+1.41%↑

SHL.DE

42.36

+0.19%↑

PHIA

27.11

+0.82%↑

SRT3

239.4

+0.59%↑

ORNBV.FI

67.7

0%↓

SAN

82.08

+1.41%↑

SHL.DE

42.36

+0.19%↑

PHIA

27.11

+0.82%↑

SRT3

239.4

+0.59%↑

ORNBV.FI

67.7

0%↓

SAN

82.08

+1.41%↑

SHL.DE

42.36

+0.19%↑

PHIA

27.11

+0.82%↑

SRT3

239.4

+0.59%↑

ORNBV.FI

67.7

0%↓

SAN

82.08

+1.41%↑

SHL.DE

42.36

+0.19%↑

PHIA

27.11

+0.82%↑

SRT3

239.4

+0.59%↑

ORNBV.FI

67.7

0%↓

SAN

82.08

+1.41%↑

SHL.DE

42.36

+0.19%↑

PHIA

27.11

+0.82%↑

SRT3

239.4

+0.59%↑

ORNBV.FI

67.7

0%↓

Search

Vetoquinol SA

Fermé

SecteurSoins de santé

84.4 -0.47

Résumé

Variation du prix de l'action

24h

Actuel

Min

84.3

Max

84.4

Chiffres clés

By Trading Economics

Revenu

25M

Ventes

258M

P/E

Moyenne du Secteur

16.706

108.767

Rendement du dividende

1.03

Marge bénéficiaire

9.734

Employés

2,497

EBITDA

48M

Dividendes

By Dow Jones

Rendement du dividende

Moyenne du Secteur

1.03%

2.21%

Prochains Résultats

27 mars 2026

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

1B

Ouverture précédente

84.87

Clôture précédente

84.4

Sentiment de l'Actualité

By Acuity

50%

50%

139 / 352 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Bearish Evidence

Vetoquinol SA Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

27 févr. 2026, 23:53 UTC

Actions en Tendance

Stocks to Watch: Aardvark Therapeutics, Blue Moon Metals

27 févr. 2026, 22:23 UTC

Acquisitions, Fusions, Rachats

Blue Moon Metals To Acquire Apex Germanium Mine From Teck Subsidiary

28 févr. 2026, 21:36 UTC

Résultats
Acquisitions, Fusions, Rachats

Berkshire Hathaway Operating Earnings Fell 30% in Fourth Quarter. There Were No Stock Buybacks. -- Barrons.com

28 févr. 2026, 15:20 UTC

Résultats

Berkshire's Abel Pledges to Follow Buffett's 'Framework' in First Shareholder Letter -- 2nd Update

28 févr. 2026, 14:43 UTC

Résultats
Acquisitions, Fusions, Rachats

Berkshire Hathaway Operating Earnings Fell 30% in Fourth Quarter. There Were No Stock Buybacks. -- Barrons.com

28 févr. 2026, 14:38 UTC

Résultats
Acquisitions, Fusions, Rachats

Berkshire's Abel Pledges to Follow Buffett's 'Framework' in First Shareholder Letter -- Update

28 févr. 2026, 13:47 UTC

Résultats
Acquisitions, Fusions, Rachats

Berkshire Hathaway Operating Earnings Fell 30% in Fourth Quarter. There Were No Stock Buybacks. -- Barrons.com

28 févr. 2026, 13:44 UTC

Résultats
Acquisitions, Fusions, Rachats

Berkshire Hathaway Earnings Slip on Decline in Insurance Results -- WSJ

28 févr. 2026, 13:14 UTC

Résultats
Acquisitions, Fusions, Rachats

Berkshire Hathaway Operating Earnings Fell 30% in Fourth Quarter. There Were No Stock Buybacks. -- Barrons.com

28 févr. 2026, 02:32 UTC

Résultats
Acquisitions, Fusions, Rachats

Calpers Buys Into Hot Chip And Quantum Stocks -- Barrons.com

28 févr. 2026, 02:00 UTC

Acquisitions, Fusions, Rachats

Six Months, 9 Offers and $81 Billion. How Hollywood's Nasty Takeover Was Won. -- WSJ

28 févr. 2026, 02:00 UTC

Acquisitions, Fusions, Rachats

Six Months, 9 Offers and $81 Billion. How -2-

28 févr. 2026, 00:01 UTC

Acquisitions, Fusions, Rachats

Paramount Issuing $47 Billion of Equity at Big Premium to Stock Price for Warner Bros. Deal -- Barrons.com

27 févr. 2026, 23:46 UTC

Acquisitions, Fusions, Rachats

Netflix Walks Away a Winner After Losing Warner Bros. to Paramount -- Barrons.com

27 févr. 2026, 23:33 UTC

Acquisitions, Fusions, Rachats

Paramount Issuing $47 Billion of Equity at Nearly 20% Premium to Current Stock Price -- Barrons.com

27 févr. 2026, 21:50 UTC

Market Talk
Acquisitions, Fusions, Rachats

Tech, Media & Telecom Roundup: Market Talk

27 févr. 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

27 févr. 2026, 21:30 UTC

Résultats

Solventum Beat Wall Street Earnings Estimates. The Stock Falls. -- Barrons.com

27 févr. 2026, 21:30 UTC

Market Talk
Acquisitions, Fusions, Rachats

Warner Terminates Netflix Deal, Ending Monthslong Saga -- Market Talk

27 févr. 2026, 21:20 UTC

Acquisitions, Fusions, Rachats

Blue Moon Metals to Buy Apex Germanium and Gallium Mine From Teck >BMM

27 févr. 2026, 21:17 UTC

Résultats

These Stocks Are Today's Movers: Netflix, Paramount, Block, Sunrun, Dell, Rocket Lab, Nvidia, CoreWeave, and More -- Barrons.com

27 févr. 2026, 21:10 UTC

Acquisitions, Fusions, Rachats

Blue Moon Metals Evaluating Options for a New Processing Line at Springer Complex to Process the Apex Material

27 févr. 2026, 21:09 UTC

Acquisitions, Fusions, Rachats

Blue Moon Metals to Acquire the Apex Germanium and Gallium Mine From Teck

27 févr. 2026, 21:00 UTC

Résultats

Nike: 3Q Results to Be Released March 31 to Accommodate for Several Holidays >NKE

27 févr. 2026, 20:31 UTC

Acquisitions, Fusions, Rachats

Netflix Receives $2.8B Termination Fee Under Terminated Warner Bros. Discovery Deal

27 févr. 2026, 20:24 UTC

Market Talk

Oil Gains on Increased Risk of U.S.-Iran Conflict -- Market Talk

27 févr. 2026, 20:23 UTC

Market Talk

U.S. Natural Gas Futures Post Modest Gains -- Market Talk

27 févr. 2026, 20:12 UTC

Market Talk

Nike Seen With Further Challenges in China -- Market Talk

27 févr. 2026, 19:44 UTC

Market Talk

Gold Caps Historic Month -- Market Talk

27 févr. 2026, 19:39 UTC

Résultats

These Stocks Are Today's Movers: Netflix, Paramount, Block, Sunrun, Dell, Rocket Lab, Nvidia, CoreWeave, and More -- Barrons.com

Comparaison

Variation de prix

Vetoquinol SA prévision

Note du Consensus

By TipRanks

0 ratings

0

Achat

0

Maintien

0

Vente

Score Technique

By Trading Central

72.6 / 75.1Support & Résistance

Court Terme

Bearish Evidence

Moyen Terme

Bearish Evidence

Long Terme

Bearish Evidence

Sentiment

By Acuity

139 / 352Classement par Soins de santé

Sentiment de l'Actualité

Neutral

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Vetoquinol SA

Vetoquinol SA, a veterinary pharmaceutical company, designs, develops, and sells veterinary drugs and non-medicinal products in Europe, the Americas, and the Asia Pacific region. It provides products in the areas of mobility, pain, and inflammation; dermatology, hygiene, and care; anti-parasite; udder health; infectious diseases; reproduction; behavior management; internal medicine; and cardiology-nephrology for cattle, sheep, pigs, poultry, dogs, cats, and horses. The company was founded in 1933 and is headquartered in Lure, France. Vetoquinol SA is a subsidiary of Soparfin SCA.
help-icon Live chat